$2.41 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest



Vaxxinity, Inc. is a biotechnology company. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) enables a new class of therapeutics that seeks to improve access to treatments for a range of indications. Its pipeline consists of five chronic disease product candidates from early to late-stage development across multiple therapeutic areas, including Alzheimer's Disease (AD), Parkinson's Disease (PD), migraine and hypercholesterolemia. Its UB-311 targets toxic forms of aggregated amyloid-b (Ab) in the brain to fight AD. Its UB-312 targets toxic forms of aggregated a-synuclein in the brain to fight PD and other synucleinopathies, such as Lewy body dementia (LBD) and multiple system atrophy (MSA). Its UB-313 targets Calcitonin Gene-Related Peptide (CGRP) to fight migraines. Its Anti-PCSK9 targets proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) to lower low-density lipoprotein (LDL) cholesterol and reduce the risk of cardiac events.

Stock Analysis

last close $2.38
1-mo return 36.8%
3-mo return -41.5%
avg daily vol. 267.02T
52-week high 22.77
52-week low 1.51
market cap. $267M
forward pe -
annual div. -
roe -677%
ltg forecast -
dividend yield -
annual rev. $0M
inst own. 22.4%

Subscribe now for daily local and international financial news